NASDAQ : ABUS
Arbutus Biopharma Corporation — Financial statements
Healthcare · Biotechnology · United States
Last price 4.21 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 832.94M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Arbutus Biopharma Corporation (ABUS) reported revenue of 181.72M USD (TTM). Five years of income statement, balance sheet, cash flow and ratios below.
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Revenue | 181.72M | 14.08M | 6.17M | 18.14M | 39.02M | 10.99M |
| Cost of Revenue | 17.80M | 25.24M | 54.04M | 73.70M | 84.41M | 65.50M |
| Gross Profit | 163.92M | -11.16M | -47.87M | -55.56M | -45.39M | -54.51M |
| Selling, General & Admin | 16.49M | 15.89M | 22.11M | 22.48M | 17.83M | 17.14M |
| Operating Expenses | 16.49M | 15.89M | 22.11M | 22.48M | 17.83M | 17.14M |
| Operating Income | 147.43M | -27.05M | -69.97M | -78.03M | -63.22M | -71.65M |
| Interest Expense | -76.00K | -97.00K | -137.00K | -459.00K | -1.73M | -2.86M |
| Interest & Investment Income | 3.49M | 4.07M | 6.58M | 5.69M | 2.19M | 127.00K |
| Currency Exchange Gain (Loss) | -25.00K | 14.00K | -49.00K | 25.00K | -22.00K | 5.00K |
| EBT Excluding Unusual Items | 150.81M | -23.07M | -63.58M | -72.78M | -62.78M | -74.38M |
| Merger & Restructuring Charges | -401.00K | -12.94M | -3.72M | |||
| Gain (Loss) on Sale of Assets | 674.00K | 674.00K | ||||
| Other Unusual Items | 1.97M | 1.83M | -2.62M | -69.00K | -2.23M | -1.87M |
| Pretax Income | 153.05M | -33.50M | -69.92M | -72.85M | -65.01M | -76.25M |
| Income Tax Expense | 4.44M | |||||
| Net Income | 153.05M | -33.50M | -69.92M | -72.85M | -69.46M | -76.25M |
| Preferred Dividends & Other Adjustments | 12.14M | |||||
| Net Income to Common | 153.05M | -33.50M | -69.92M | -72.85M | -69.46M | -88.39M |
| Shares Outstanding (Basic) | 193.85M | 191.60M | 185.61M | 165.96M | 150.94M | 106.24M |
| Shares Outstanding (Diluted) | 194.46M | 191.60M | 185.61M | 165.96M | 150.94M | 106.24M |
| EPS (Basic) | 0.79 | -0.17 | -0.38 | -0.44 | -0.46 | -0.83 |
| EPS (Diluted) | 0.79 | -0.17 | -0.38 | -0.44 | -0.46 | -0.83 |
| Free Cash Flow | -24.62M | -39.64M | -65.03M | -86.94M | -35.87M | -68.34M |
| Free Cash Flow Per Share | -0.13 | -0.21 | -0.35 | -0.52 | -0.24 | -0.64 |
| Gross Margin | 90.20% | -79.23% | -116.32% | |||
| Operating Margin | 81.13% | -192.08% | -1,133.92% | -430.15% | -162.03% | -652.07% |
| Profit Margin | 84.23% | -237.88% | -1,133.04% | -401.57% | -178.01% | -804.39% |
| Free Cash Flow Margin | -13.55% | -281.45% | -1,053.83% | -479.27% | -91.92% | -621.96% |
| EBITDA | 147.47M | -26.69M | -68.59M | -76.63M | -61.80M | -69.90M |
| EBITDA Margin | 81.15% | -189.50% | -158.37% | |||
| D&A For EBITDA | 44.00K | 363.00K | 1.38M | 1.40M | 1.43M | 1.75M |
| EBIT | 147.43M | -27.05M | -69.97M | -78.03M | -63.22M | -71.65M |
| EBIT Margin | 81.13% | -192.08% | -162.03% | |||
| Revenue as Reported | 181.72M | 14.08M | 6.17M | 18.14M | 39.02M | 10.99M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 19.17M | 18.01M | 36.33M | 26.29M | 30.78M | 109.28M |
| Short-Term Investments | 73.45M | 73.46M | 86.29M | 99.72M | 116.14M | 46.03M |
| Cash & Short-Term Investments | 92.62M | 91.47M | 122.62M | 126.00M | 146.91M | 155.32M |
| Accounts Receivable | 179.74M | 1.45M | 2.41M | 1.78M | 1.35M | 899.00K |
| Other Receivables | 400.00K | 300.00K | 300.00K | 600.00K | ||
| Receivables | 180.14M | 1.75M | 2.71M | 2.38M | 1.35M | 899.00K |
| Prepaid Expenses | 1.12M | 1.24M | 1.98M | 3.65M | 2.87M | 4.45M |
| Total Current Assets | 273.88M | 94.46M | 127.32M | 132.03M | 151.14M | 160.66M |
| Property, Plant & Equipment | 10.00K | 32.00K | 4.36M | 6.09M | 6.81M | 8.07M |
| Long-Term Investments | 6.28M | 37.36M | 35.69M | |||
| Other Long-Term Assets | 132.00K | 130.00K | 34.00K | 103.00K | 61.00K | |
| Total Assets | 274.02M | 94.62M | 131.71M | 144.40M | 195.42M | 204.49M |
| Accounts Payable | 373.00K | 1.17M | 2.32M | 3.22M | 3.52M | 3.17M |
| Accrued Expenses | 2.32M | 3.65M | 5.25M | 7.05M | 12.51M | 7.66M |
| Current Portion of Leases | 514.00K | 547.00K | 483.00K | 425.00K | 372.00K | 383.00K |
| Current Unearned Revenue | 7.57M | 11.79M | 16.46M | |||
| Other Current Liabilities | 160.00K | 640.00K | ||||
| Total Current Liabilities | 3.36M | 6.01M | 15.62M | 22.49M | 32.86M | 11.22M |
| Long-Term Debt | 3.11M | 3.44M | 4.83M | 6.95M | 10.37M | 16.30M |
| Long-Term Leases | 199.00K | 806.00K | 1.34M | 1.81M | 2.23M | |
| Long-Term Unearned Revenue | 2.86M | 6.00M | ||||
| Other Long-Term Liabilities | 8.82M | 8.39M | 10.22M | 7.60M | 7.53M | 5.30M |
| Total Liabilities | 15.29M | 18.04M | 34.34M | 38.38M | 58.57M | 35.05M |
| Common Stock | 1.45B | 1.42B | 1.41B | 1.35B | 1.32B | 1.29B |
| Additional Paid-In Capital | 74.32M | 83.32M | 82.05M | 81.27M | 72.41M | 65.48M |
| Retained Earnings | -1.22B | -1.38B | -1.35B | -1.28B | -1.20B | -1.13B |
| Comprehensive Income & Other | -48.24M | -48.10M | -48.13M | -48.42M | -50.49M | -48.34M |
| Total Common Equity | 258.73M | 76.58M | 97.37M | 106.02M | 136.85M | 169.44M |
| Shareholders' Equity | 258.73M | 76.58M | 97.37M | 106.02M | 136.85M | 169.44M |
| Total Liabilities & Equity | 274.02M | 94.62M | 131.71M | 144.40M | 195.42M | 204.49M |
| Total Debt | 3.62M | 4.19M | 6.12M | 8.72M | 12.55M | 18.91M |
| Net Cash (Debt) | 89.00M | 87.28M | 116.50M | 123.57M | 171.72M | 172.09M |
| Net Cash Per Share | 0.46 | 0.46 | 0.63 | 0.74 | 1.14 | 1.62 |
| Filing Date Shares Outstanding | 197.85M | 195.48M | 191.48M | 179.49M | 162.57M | 148.64M |
| Total Common Shares Outstanding | 197.63M | 192.53M | 189.96M | 169.87M | 157.46M | 144.99M |
| Working Capital | 270.52M | 88.45M | 111.70M | 109.54M | 118.28M | 149.44M |
| Book Value Per Share | 1.31 | 0.40 | 0.51 | 0.62 | 0.87 | 1.17 |
| Tangible Book Value | 258.73M | 76.58M | 97.37M | 106.02M | 136.85M | 169.44M |
| Tangible Book Value Per Share | 1.31 | 0.40 | 0.51 | 0.62 | 0.87 | 1.17 |
| Machinery | 245.00K | 7.71M | 7.98M | 7.28M | 6.79M | |
| Leasehold Improvements | 8.59M | 8.59M | 8.59M | 8.56M |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | 153.05M | -33.50M | -69.92M | -72.85M | -69.46M | -76.25M |
| Depreciation & Amortization | 44.00K | 363.00K | 1.38M | 1.40M | 1.43M | 1.75M |
| Loss (Gain) From Sale of Assets | -674.00K | -674.00K | -20.00K | |||
| Asset Writedown & Restructuring Costs | 2.81M | 167.00K | ||||
| Loss (Gain) From Sale of Investments | -1.64M | -2.35M | -3.13M | -2.20M | -54.00K | 999.00K |
| Stock-Based Compensation | 5.51M | 6.95M | 8.99M | 9.30M | 7.18M | 6.42M |
| Other Operating Activities | -2.77M | -3.22M | 501.00K | -3.34M | -3.70M | -1.39M |
| Change in Accounts Receivable | 1.07M | 1.38M | -633.00K | -424.00K | -453.00K | 413.00K |
| Change in Accounts Payable | -1.66M | -2.10M | -2.71M | -5.76M | 5.22M | 1.91M |
| Change in Unearned Revenue | -10.43M | -1.36M | -10.66M | 22.45M | ||
| Change in Other Net Operating Assets | -177.56M | 1.14M | 1.87M | -1.39M | 2.02M | -1.40M |
| Operating Cash Flow | -24.62M | -39.64M | -64.85M | -85.94M | -35.36M | -67.53M |
| Capital Expenditures | -182.00K | -1.01M | -512.00K | -809.00K | ||
| Sale of Property, Plant & Equipment | 355.00K | 364.00K | 20.00K | |||
| Investment in Securities | -11.20M | 15.22M | 23.13M | 51.76M | -74.43M | -11.87M |
| Investing Cash Flow | -10.84M | 15.58M | 22.95M | 50.77M | -74.94M | -12.68M |
| Issuance of Common Stock | 17.25M | 5.72M | 52.00M | 30.65M | 31.81M | 137.24M |
| Financing Cash Flow | 17.25M | 5.72M | 52.00M | 30.65M | 31.81M | 137.24M |
| Foreign Exchange Rate Adjustments | -25.00K | 14.00K | -49.00K | 25.00K | -22.00K | 5.00K |
| Net Cash Flow | -18.24M | -18.32M | 10.04M | -4.49M | -78.51M | 57.03M |
| Free Cash Flow | -24.62M | -39.64M | -65.03M | -86.94M | -35.87M | -68.34M |
| Free Cash Flow Margin | -13.55% | -281.45% | -1,053.83% | -479.27% | -91.92% | -621.96% |
| Free Cash Flow Per Share | -0.13 | -0.21 | -0.35 | -0.52 | -0.24 | -0.64 |
| Levered Free Cash Flow | -80.24M | -17.62M | -39.23M | -51.58M | -9.73M | -38.42M |
| Unlevered Free Cash Flow | -80.19M | -17.56M | -39.15M | -51.30M | -8.65M | -36.63M |
| Change in Working Capital | -178.15M | -10.02M | -2.83M | -18.23M | 29.24M | 925.00K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 791.39M | 925.08M | 619.64M | 419.24M | 364.57M | 526.20M |
| Enterprise Value | 702.39M | 835.98M | 495.64M | 284.58M | 189.05M | 555.86M |
| Last Close Price | 4.00 | 4.81 | 3.27 | 2.50 | 2.33 | 3.89 |
| Forward PE | 236.87 | 236.87 | 236.87 | 236.87 | 236.87 | |
| PS Ratio | 4.36 | 65.69 | 100.41 | 23.11 | 9.34 | 47.89 |
| PB Ratio | 3.06 | 12.08 | 6.36 | 3.95 | 2.66 | 3.11 |
| P/TBV Ratio | 3.06 | 12.08 | 6.36 | 3.95 | 2.66 | 3.11 |
| EV/Sales Ratio | 3.87 | 59.36 | 80.32 | 15.69 | 4.84 | 50.59 |
| Debt / Equity Ratio | 0.01 | 0.06 | 0.06 | 0.08 | 0.09 | 0.11 |
| Net Debt / Equity Ratio | -0.34 | -1.14 | -1.20 | -1.17 | -1.25 | -1.02 |
| Net Debt / EBITDA Ratio | -0.60 | 3.27 | 1.70 | 1.61 | 2.78 | 2.46 |
| Net Debt / FCF Ratio | 3.61 | 2.20 | 1.79 | 1.42 | 4.79 | 2.52 |
| Asset Turnover | 0.96 | 0.12 | 0.04 | 0.11 | 0.20 | 0.06 |
| Quick Ratio | 81.08 | 15.52 | 8.03 | 5.71 | 4.51 | 13.92 |
| Current Ratio | 81.42 | 15.73 | 8.15 | 5.87 | 4.60 | 14.32 |
| Return on Equity (ROE) | 89.58% | -38.52% | -68.76% | -59.99% | -45.35% | -56.19% |
| Return on Assets (ROA) | 48.84% | -14.94% | -31.68% | -28.70% | -19.76% | -26.22% |
| Return on Capital Employed (ROCE) | 54.50% | -30.50% | -60.30% | -64.00% | -38.90% | -37.10% |
| Earnings Yield | 19.74% | -3.62% | -11.28% | -17.38% | -19.05% | -14.49% |
| FCF Yield | -3.11% | -4.29% | -10.50% | -20.74% | -9.84% | -12.99% |
| Buyback Yield / Dilution | -2.21% | -3.23% | -11.84% | -9.95% | -42.07% | -40.10% |